The Myeloma Institute for Research and Therapy is the number one choice for myeloma treatment throughout the world. Our physicians and scientists have one overriding goal: to achieve cure in patients with multiple myeloma.
Our history of conducting research and delivering therapy has brought about fundamental changes in the approach to treating myeloma. As a result, we have seen substantial improvements in patient outcomes, including response to treatments, remission, and long-term survival.
At the Myeloma Institute patients diagnosed with low-risk multiple myeloma typically experience more than a decade of survival. Patients with high-risk multiple myeloma benefit from new therapies discovered with our translational research. Patients receive therapies targeted to specific molecular subtypes of myeloma, allowing them to receive the most effective treatment with the minimum amount of side effects. Most patients are treated on an outpatient basis, even when stem-cell transplant is part of the treatment regimen. Many of our patients are participants in our ground-breaking clinical trials.
View our enrolling clinical trials here.
Explore the links at the left to learn more about treatment at the Myeloma Institute.